Critical Analysis: Bone Biologics (BBLG) & The Competition

Bone Biologics (OTC:BBLGGet Free Report) is one of 125 publicly-traded companies in the “Medical Devices” industry, but how does it compare to its competitors? We will compare Bone Biologics to similar companies based on the strength of its dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares Bone Biologics and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Bone Biologics N/A -$1.49 million -0.08
Bone Biologics Competitors $525.84 million $22.89 million 82.78

Bone Biologics’ competitors have higher revenue and earnings than Bone Biologics. Bone Biologics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Bone Biologics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, Bone Biologics’ competitors have a beta of 0.78, indicating that their average stock price is 22% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Bone Biologics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bone Biologics 0 0 1 0 3.00
Bone Biologics Competitors 185 1000 1046 40 2.41

Bone Biologics presently has a consensus target price of $67.50, suggesting a potential upside of 9,021.62%. As a group, “Medical Devices” companies have a potential upside of 80.64%. Given Bone Biologics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Bone Biologics is more favorable than its competitors.


This table compares Bone Biologics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bone Biologics N/A -123.44% -82.64%
Bone Biologics Competitors -55.34% -36.16% -13.66%

Insider and Institutional Ownership

25.7% of shares of all “Medical Devices” companies are owned by institutional investors. 7.9% of Bone Biologics shares are owned by company insiders. Comparatively, 26.7% of shares of all “Medical Devices” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


Bone Biologics competitors beat Bone Biologics on 9 of the 13 factors compared.

About Bone Biologics

(Get Free Report)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with's FREE daily email newsletter.